Head-to-head · WeighScore
Nucore Health vs Zealthy
The verdict
Nucore Health takes it — 58.6/100 to 46.7/100.
Nucore Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nucore Health is a physician-owned, LegitScript-certified telehealth platform serving all 50 states, focused on GLP-1 and longevity care: compounded semaglutide and tirzepatide (including a microdose…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Nucore Health | Zealthy |
|---|---|---|
| WeighScore | 58.6/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #367 | #496 |
| Semaglutide | $299/mo (starting dose, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $199/mo (microdose tier, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #367 · C
Strengths
- Physician-owned and LegitScript Certified — strong trust signals
- Available nationwide in all 50 states
- Care and pharmacy fulfillment run on OpenLoop Health's licensed network
- Broad menu — compounded GLP-1, microdose tirzepatide, NAD+, sermorelin, MIC B12
Where it loses points
- Published pricing is gated behind the intake quiz — no upfront cost shown
- Legal terms and privacy are posted as downloadable documents, not web pages
- Compounded GLP-1 is not FDA-approved and prescribed off-label (per their own notice)
- Longevity and microdose positioning is marketing; evidence varies by use
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.